Emerging options in the treatment of deep vein thrombosis and pulmonary embolism

Cohen, 2007, Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality, Thromb Haemost, 98, 756, 10.1160/TH07-03-0212 Heit, 2005, on Behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal Venous Thromboembolism (VTE) Events in the US, Blood, 106, 910a, 10.1182/blood.V106.11.910.910 Prandoni, 1996, The long-term clinical course of acute deep venous thrombosis, Ann Intern Med, 125, 1, 10.7326/0003-4819-125-1-199607010-00001 Kearon, 2003, Natural history of venous thromboembolism, Circulation, 107, I22, 10.1161/01.CIR.0000078464.82671.78 Kahn, 2004, Relationship between deep venous thrombosis and the postthrombotic syndrome, Arch Intern Med, 164, 17, 10.1001/archinte.164.1.17 Bounameaux, 2009, The novel anticoagulants: entering a new era, Swiss Med Wkly, 139, 60 Kearon, 2008, Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), Chest, 133, 454S, 10.1378/chest.08-0658 Hirsh, 2008, Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), Chest, 133, 141S, 10.1378/chest.08-0689 Warkentin, 1995, Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin, N Engl J Med, 332, 1330, 10.1056/NEJM199505183322003 Griffith, 1965, Heparin osteoporosis, JAMA, 193, 91, 10.1001/jama.1965.03090020005001 Kelton, 1988, Heparin-induced thrombocytopenia: laboratory studies, Blood, 72, 925, 10.1182/blood.V72.3.925.bloodjournal723925 Warkentin, 2008, Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), Chest, 133, 340S, 10.1378/chest.08-0677 Warkentin, 2006, Think of HIT, Hematology Am Soc Hematol Educ Program, 408, 10.1182/asheducation-2006.1.408 Warkentin, 1994, Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia, Blood, 84, 3691, 10.1182/blood.V84.11.3691.bloodjournal84113691 Wawrzynska, 2003, Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism, Pathophysiol Haemost Thromb, 33, 64, 10.1159/000073848 Shaughnessy, 1995, The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria, Blood, 86, 1368, 10.1182/blood.V86.4.1368.bloodjournal8641368 Samama, 2010, Newer anticoagulants in 2009, J Thromb Thrombolysis, 29, 92, 10.1007/s11239-009-0392-5 Ansell, 2008, Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), Chest, 133, 160S, 10.1378/chest.08-0670 Takahashi, 2006, Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans, Pharmacogenet Genomics, 16, 101, 10.1097/01.fpc.0000184955.08453.a8 Kamali, 2004, Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin, Clin Pharmacol Ther, 75, 204, 10.1016/j.clpt.2003.10.001 Franco, 2004, Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols, Am J Med, 116, 651, 10.1016/j.amjmed.2003.12.036 Blann, 1999, Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0, Br J Haematol, 107, 207, 10.1046/j.1365-2141.1999.01672.x Caprini, 2005, Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs, J Vasc Surg, 42, 726, 10.1016/j.jvs.2005.05.053 Arepally G, Bauer KA, Bhatt DL, Merli GJ, Naccarelli GV, Carter RD, et al. The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education. Crit Pathw Cardiol 2010; 9: 41–48. Gross, 2003, Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey, Clin Ther, 25, 1750, 10.1016/S0149-2918(03)80167-4 Caprini, 2006, Compliance with antithrombotic guidelines, Manag Care, 15 Vats, 2007, Survey of hospitals for guidelines, policies, and protocols for anticoagulants, Am J Health Syst Pharm, 64, 1203, 10.2146/ajhp060264 Jiang, 2009, Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro, Thromb Haemost, 101, 780, 10.1160/TH08-07-0486 Shantsila, 2008, Apixaban, an oral, direct inhibitor of activated Factor Xa, Curr Opin Investig Drugs, 9, 1020 He, 2006, Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor, Blood, 108, 910a, 10.1182/blood.V108.11.910.910 Frost, 2007, Apixaban does not affect the pharmacokinetics of digoxin, J Clin Pharmacol, 47, 60a Carreiro, 2008, Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict, Expert Opin Investig Drugs, 17, 1937, 10.1517/13543780802528625 Luettgen, 2006, In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor Xa inhibitor, Blood, 108, 4130a, 10.1182/blood.V108.11.4130.4130 Raghavan, 2009, Apixaban metabolism and pharmacokinetics after oral administration to humans, Drug Metab Dispos, 37, 74, 10.1124/dmd.108.023143 Frost, 2008, Apixaban, a direct factor Xa inhibitor: single dose pharmacokinetics and pharmacodynamics of an intravenous formulations, J Clin Pharmacol, 48, 1132 Lassen, 2009, Apixaban or enoxaparin for thromboprophylaxis after knee replacement, N Engl J Med, 361, 594, 10.1056/NEJMoa0810773 Lassen, 2010, Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial, Lancet, 375, 807, 10.1016/S0140-6736(09)62125-5 Lassen, 2010, Apixaban versus enoxaparin for thromboprophylaxis after hip replacement, N Engl J Med, 363, 2487, 10.1056/NEJMoa1006885 Connolly, 2011, Apixaban in patients with atrial fibrillation, N Engl J Med, 364, 806, 10.1056/NEJMoa1007432 Perzborn, 2005, In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor, J Thromb Haemost, 3, 514, 10.1111/j.1538-7836.2005.01166.x Varin, 2009, Effect of rivaroxaban, an oral direct factor Xa inhibitor, on whole blood clot permeation and thrombolysis: critical role of red blood cells, Blood, 114, 1064a, 10.1182/blood.V114.22.1064.1064 Mueck, 2007, Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor xa inhibitor—in healthy subjects, Int J Clin Pharmacol Ther, 45, 335, 10.5414/CPP45335 Kubitza, 2006, Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects, J Clin Pharmacol, 46, 549, 10.1177/0091270006286904 Kubitza, 2007, Rivaroxaban (BAY 59-7939)—an oral, direct Factor Xa inhibitor—has no clinically relevant interaction with naproxen, Br J Clin Pharmacol, 63, 469, 10.1111/j.1365-2125.2006.02776.x Kubitza, 2007, Co-administration of rivaroxaban—a novel, oral, direct Factor Xa inhibitor—and clopidogrel in healthy subjects, Eur Heart J, 28, 1272a Kubitza, 2007, Rivaroxaban—a novel, oral, direct Factor Xa inhibitor has no clinically relevant interaction with acetylsalicylic acid or naproxen, J Thromb Haemost, 5 Kubitza, 2006, No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin, J Clin Pharmacol, 46, 11a Kubitza, 2008, No interaction between rivaroxaban—a novel, oral, direct factor Xa inhibitor—and atorvastatin, Pathophysiol Haemost Thromb, 36, 40a Eriksson, 2008, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty, N Engl J Med, 358, 2765, 10.1056/NEJMoa0800374 Kakkar, 2008, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial, Lancet, 372, 31, 10.1016/S0140-6736(08)60880-6 Lassen, 2008, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty, N Engl J Med, 358, 2776, 10.1056/NEJMoa076016 Turpie, 2009, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial, Lancet, 373, 1673, 10.1016/S0140-6736(09)60734-0 Bauersachs, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, 2499, 10.1056/NEJMoa1007903 Buller, 2009, Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The Einstein-extension study, Blood, 114, 10.1182/blood.V114.22.LBA-2.LBA-2 Blech, 2008, The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans, Drug Metab Dispos, 36, 386, 10.1124/dmd.107.019083 Stangier, 2008, Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate, Clin Pharmacokinet, 47, 285, 10.2165/00003088-200847050-00001 Eriksson, 2007, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, J Thromb Haemost, 5, 2178, 10.1111/j.1538-7836.2007.02748.x Ginsberg, 2009, Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery, J Arthroplasty, 24, 1, 10.1016/j.arth.2008.01.132 Eriksson, 2007, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, Lancet, 370, 949, 10.1016/S0140-6736(07)61445-7 Schulman, 2009, Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N Engl J Med, 361, 2342, 10.1056/NEJMoa0906598 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Lu, 2009, Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors, J Thromb Haemost, 7 Perzborn, 2007, Recombinant Factor VIIa partially reverses the effects of the Factor Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro, J Thromb Haemost, 5 Gruber, 2008, Potential of activated prothrombin complex concentrate and activated Factor VII to reverse the anticoagulant effects of rivaroxaban in primates, Blood, 112, 3825a, 10.1182/blood.V112.11.3825.3825 Perzborn, 2009, Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats, J Thromb Haemost, 7 Harder, 2008, Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications, Thromb Res, 123, 396, 10.1016/j.thromres.2008.05.010 Wong, 2008, Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies, J Thromb Haemost, 6, 820, 10.1111/j.1538-7836.2008.02939.x Samama, 2010, Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor, Thromb Haemost, 103, 815, 10.1160/TH09-03-0176 Stangier, 2007, The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects, Br J Clin Pharmacol, 64, 292, 10.1111/j.1365-2125.2007.02899.x